EU starts real-time review of AstraZeneca COVID-19 antibody cocktail
Europe's drug regulator said on Thursday it had started a real-time review of the antibody-based COVID-19 therapy developed by AstraZeneca, roughly a week after the Anglo-Swedish drugmaker sought emergency approval from U.S. authorities.
The decision to begin the assessment by the human medicines committee of the European Medicines Agency (EMA) was based on early results from clinical studies, the regulator said in a statement, without specifying when a conclusion was expected. The medicine, the first protective shot other than vaccines against COVID-19, has proven to work in the non-infected and was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
"EMA will evaluate more data on the quality, safety, and effectiveness of the medicine as they become available," the watchdog said, adding that the rolling review would continue until AstraZeneca submits a formal application for approval.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- AstraZeneca
- Anglo
- European Medicines Agency
- U.S.
- Europe
ALSO READ
BRIEF-AstraZeneca To Acquire Amolyt Pharma
AstraZeneca bets on next-generation cancer therapy with $2 bln Fusion deal
BRIEF-Ofgem Announces Anglo-Scottish Electricity Superhighway Funding
Health News Roundup: AstraZeneca to cap out-of-pocket inhaler costs in US, following rival Boehringer's move; Kroger to sell specialty pharmacy business to Elevance Health's CarelonRx and more